Haematology-OncologyWorkshop recording2026
International Myeloma Society Educational Workshop Belgrade 2026 — myeloma care from diagnosis to post-CAR-T relapse
The International Myeloma Society Educational Workshop in Belgrade, Serbia 2026 packs two days, 13–14 March 2026, of plasma cell disorder teaching into 27 sessions co-organised by the Serbian Myeloma Group and the Balkan Myeloma Study Group. Lectures on diagnostics, MRD, transplant decisions, sequencing, CAR T cells and bispecifics alternate with live panels in which the faculty argue through real management questions. Waldenström’s macroglobulinaemia, AL amyloidosis and supportive care get their own blocks.
- 27sessions
- 8programme blocks
- 7live panel discussions
- Mar 2026Belgrade
What you’ll be able to do
- Order the right diagnostic work-up, imaging and MRD testing for suspected or treated myeloma
- Apply new risk models for smoldering and newly diagnosed disease
- Choose induction for transplant-eligible and ineligible patients
- Sequence therapy at first and second relapse
- Place CAR T cells and bispecific T-cell engagers in everyday practice
- Handle bone disease, renal failure, infection and vaccination, plus frailty-adjusted plans
Inside the workshop
Biology, diagnosis and risk
Two plenaries frame the disease from biology to future directions, then four talks on testing, imaging, MRD and risk stratification end with a panel on follow-up.
Treating early and relapsed disease
Blocks on smoldering and newly diagnosed myeloma, then relapsed and refractory disease, cover transplant eligibility, sequencing and agents beyond cellular therapy and bispecifics.
International Myeloma Society immunotherapy block
Dedicated sessions on CAR T cells and bispecific T-cell engagers are followed by a panel on how to integrate them safely into routine care.
Complications, other dysproteinaemias and hard cases
Supportive care, Waldenström’s and AL amyloidosis precede a closing set on relapse after T-cell redirection, extramedullary disease, plasma cell leukaemia and frailty.
Built for
- Haematologists and oncologistsA current, practical synthesis of myeloma management in one programme.
- Transplant and cellular therapy physiciansFocused discussion of eligibility, CAR T and bispecific use.
- Fellows and residentsA structured overview of plasma cell disorders from diagnosis onwards.
- HaematopathologistsContext for how MRD and risk results change treatment decisions.
Programme
Sessions by block 27 sessions
- Plenary — From Biology to Therapy: The Current Landscape of Multiple Myeloma
- Plenary — The Future of Multiple Myeloma
- Diagnosis & monitoring — Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up
- Diagnosis & monitoring — Updates and Recommendations on Imaging Techniques in Myeloma
- Diagnosis & monitoring — MRD Testing in Multiple Myeloma
- Diagnosis & monitoring — New Risk Stratification in Smoldering and Multiple Myeloma
- Diagnosis & monitoring — Live Panel Discussion: Diagnosis and Follow-up of Patients
- SMM & NDMM — Management of Clinical Significance and Smoldering Myeloma
- SMM & NDMM — Management of Newly Diagnosed Multiple Myeloma: Transplant Eligible
- SMM & NDMM — Management of Newly Diagnosed Multiple Myeloma: Non-Transplant Eligible
- SMM & NDMM — Live Panel Discussion: How to Manage SMM and NDMM
- RRMM — Optimal Sequencing for RRMM Patients in First and Second Relapse
- RRMM — Novel Treatments for Multiple Myeloma Beyond Cell Therapies and Bispecifics
- RRMM — Live Panel Discussion: Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
- Novel immune strategies — CAR T Cells
- Novel immune strategies — Bispecific T-Cell Engagers
- Novel immune strategies — Live Panel Discussion: Incorporating Novel Immunotherapies into Practice
- Supportive care — Bone Disease and Renal Failure
- Supportive care — Infection and Vaccinations
- Supportive care — Live Panel Discussion: Managing Myeloma-Related Complications
- Other plasma cell disorders — Waldenström’s Macroglobulinemia
- Other plasma cell disorders — AL Amyloidosis
- Other plasma cell disorders — Live Panel Discussion: Managing Other Dysproteinemias
- Challenging questions — Relapse After T-Cell Redirected Therapies
- Challenging questions — Extramedullary Disease and Plasma Cell Leukemia
- Challenging questions — Incorporating Frailty into Treatment Algorithms for Multiple Myeloma
- Challenging questions — Live Panel Discussion
Before you buy
Who speaks at the Belgrade workshop, and in what format are the files?
Speaker names, file format, running time and download size are not listed for this package; only the session programme is known.
Is this pathology or clinical content?
Although it is filed under pathology, the teaching is clinical myeloma management aimed mainly at haematologists and oncologists; morphology is not a focus.
Do I get CME credit or a certificate?
No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.
Specifications
| Format | Workshop recordings |
|---|---|
| Contents | 27 sessions incl. 7 live panels |
| Event | 13–14 March 2026, Belgrade, Serbia |
| Organiser | International Myeloma Society with Balkan and Serbian groups |
| Department | Oncology |
| Delivery | Instant download · lifetime re-download |
Related products
Addiction Medicine
Obstetrics & Gynecology
Harvard Medicine
Harvard Gastrointestinal, Liver, and Pancreatic Pathology 2024
General Surgery
2025 Jason L. Hornick, M.D., Ph.D. Expert Series – Practical Soft Tissue Pathology -DocmedED
Pathology